Wing Kai Leung

US Patent:

20030237088, Dec 25, 2003

Filed:

Apr 21, 2003

Appl. No.:

10/419615

Inventors:

Douglas Macrae - Weston MA, US
Wing Leung - Arcadia CA, US
Henry Yuen - Pasadena CA, US
Andrew Duncan - Santa Monica CA, US

Assignee:

Gemstar Development Corporation

International Classification:

H04N007/16

US Classification:

725/025000

Abstract:

A television control system automatically tunes a television set to receive and display a desired program telecast at a future time. This is done by keying in a PLUS CODE™ number defining the channel, time, day, and length (CTDL data) of the program or selecting the program from an on-screen program guide to capture the CTDL data from an EPG data base stored in memory. The CTDL data is stored in a stack memory until the time of the program. The microprocessor monitors the stack memory. The microprocessor tunes the television set to the channel on which the desired program is telecast and turns the television set on at the time of the desired program. If the television set is already on at the time of the desired program, the television set is not turned off at the conclusion of the desired program, i.e., it remains on. However, if the television set is off at the time of the desired program, the television set is turned off again at the conclusion of the desired program. This results in the television set not being left on when the residents are away from home while the scheduled tuning feature is being used.

US Patent:

20200390812, Dec 17, 2020

Filed:

Dec 19, 2018

Appl. No.:

16/954912

Inventors:

- Bergisch Gladbach, DE
Markus GRANZIN - Germering, DE
Wing LEUNG - Boston MA, US
Nina MOKER - Koln, DE
Volker HUPPERT - Kurten, DE

Assignee:

MILTENYI BIOTEC B.V. & CO. KG - Bergisch Gladbach

International Classification:

A61K 35/17
C07K 14/545
C07K 14/55
C12N 15/867
C07K 14/54

Abstract:

The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.

US Patent:

20200353003, Nov 12, 2020

Filed:

Jan 4, 2019

Appl. No.:

16/959330

Inventors:

- Bergisch Gladbach, DE
Markus Granzin - Germering, DE
Wing Leung - Boston MA, US
Andrzej Dzionek - Overath, DE
Martin Meyer - Kürten, DE

International Classification:

A61K 35/17
C07K 16/28
A61K 39/395
A61P 35/00

Abstract:

The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

US Patent:

20180179490, Jun 28, 2018

Filed:

Dec 7, 2017

Appl. No.:

15/834092

Inventors:

- Bergisch Gladback, DE
Wing Leung - Cambridge MA, US
Julia Dzionek - Overath, DE
Stefan Miltenyi - Bergisch Gladbach, DE

Assignee:

Miltenyi Biotec GmbH - Bergisch Gladbach

International Classification:

C12N 5/00
C12N 5/0789
A61K 35/14
A61K 35/28
A61P 31/00
A61P 43/00
A61P 35/00
A61P 37/00

Abstract:

The invention is directed to a method for the preparation of a cell population from a sample originating from bone marrow or blood, comprising the steps a) dividing the sample into a first fraction containing 50 to 99% of the cells of the sample and a second fraction containing 50 to 1% of the cells of the sample, b) labeling the cells of the first fraction with a first marker against TCR alpha/beta, c) labeling the cells of the second fraction with a second marker against CD45RA, d) removing the labeled cells from the first and second fraction and combining the remaining cells to a cell population. Furthermore, the invention is directed to a cell composition and the use of the cell composition